XFC attenuates the neutrophil–NET–synovial cell inflammatory cascade by targeting ALKBH5 and promoting m6A methylation of LINC00968, providing an epigenetically regulated therapeutic strategy for RA treatment within a traditional medicine framework. Here, LINC00968 is linked to rheumatoid arthritis.